UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy

Alimentary pharmacology & therapeutics, 2004-01, Vol.19 (2), p.197-208

2004

Volltextzugriff (PDF)

Consequences of frequent nocturnal gastro‐oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity

Alimentary pharmacology & therapeutics, 2007-02, Vol.25 (4), p.487-500

2007

Volltextzugriff (PDF)

Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population

Neurogastroenterology and motility, 2017-05, Vol.29 (5), p.np-n/a

2017

Volltextzugriff (PDF)

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7‐year PRECiSE 3 study

Alimentary pharmacology & therapeutics, 2015-08, Vol.42 (3), p.330-342

2015

Volltextzugriff (PDF)

LIFE AFTER RADICAL PROSTATECTOMY: A LONGITUDINAL STUDY

The Journal of urology, 2001-08, Vol.166 (2), p.587-592

2001

Volltextzugriff (PDF)

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2019-08, Vol.17 (9), p.1655-1668.e3

2019

Volltextzugriff (PDF)

Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups

Inflammatory bowel diseases, 2012-12, Vol.18 (12), p.2294-2300

2012

Volltextzugriff (PDF)

DOP47 Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatment

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i157-i158

2024

Volltextzugriff (PDF)

P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i785-i786

2023

Volltextzugriff (PDF)

P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i672-i673

2023

Volltextzugriff (PDF)

P790 Assessment of steroid use in patients with active ulcerative colitis who initiated a new Janus kinase inhibitor or tumour necrosis factor inhibitor using data from a United States claims database

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1474-i1476

2024

Volltextzugriff (PDF)

P488 Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM® MarketScan

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i454-i455

2022

Volltextzugriff (PDF)

OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i037-i041

2022

Volltextzugriff (PDF)

P402 Incidence and outcomes of herpes zoster in the ozanimod phase, 3 ulcerative colitis and relapsing multiple sclerosis clinical program

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i395-i396

2022

Volltextzugriff (PDF)

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2021-12, Vol.161 (6), p.2041-2043.e1

2021

Volltextzugriff (PDF)

Variants in ZNF365 isoform D are associated with Crohn's disease

Gut, 2011-08, Vol.60 (8), p.1060-1067

2011

Volltextzugriff (PDF)

P512 Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S363-S364

2018

Volltextzugriff (PDF)

Certolizumab pegol

Nature reviews. Drug discovery, 2008-08, Vol.7 (8), p.641-642

2008

Volltextzugriff (PDF)

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7‐year PREC i SE 3 study

Alimentary pharmacology & therapeutics, 2015-08, Vol.42 (3), p.330-342

2015

Volltextzugriff (PDF)

Capsule Endoscopy: Practical Applications

Clinical gastroenterology and hepatology, 2005-05, Vol.3 (5), p.411-422

2005

Volltextzugriff (PDF)

Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM (R) MarketScan (R)

JOURNAL OF CROHNS & COLITIS, 2022, Vol.16, p.I454

2022

Volltextzugriff (PDF)

New Clinical Method for Distinguishing D-IBS from Other Gastrointestinal Conditions Causing Diarrhea: The LA/IBS Diagnostic Strategy

Digestive diseases and sciences, 2010-01, Vol.55 (1), p.145-149

2010

Volltextzugriff (PDF)

FRI0223 Development and Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) Gastrointestinal (GI) Symptom Scales in Systemic Sclerosis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.463-463

2014

Volltextzugriff (PDF)

Quality of life at the end of life: trends in patients with metastatic prostate cancer

Urology (Ridgewood, N.J.), 2002, Vol.59 (1), p.103-109

2002

Volltextzugriff (PDF)

Risk of Upper Gastrointestinal Injury and Events in Patients Treated With Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy: An Appraisal of the Literature

Journal of clinical rheumatology, 2004-08, Vol.10 (4), p.178-189

2004

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(78)

Publikationsform

Artikel
(91)
Tagungsberichte
(1)

Sprache

Englisch
(92)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy

Consequences of frequent nocturnal gastro‐oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity

Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7‐year PRECiSE 3 study

LIFE AFTER RADICAL PROSTATECTOMY: A LONGITUDINAL STUDY

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups

DOP47 Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatment

P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison

P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison

P790 Assessment of steroid use in patients with active ulcerative colitis who initiated a new Janus kinase inhibitor or tumour necrosis factor inhibitor using data from a United States claims database

P488 Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM® MarketScan

OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis

P402 Incidence and outcomes of herpes zoster in the ozanimod phase, 3 ulcerative colitis and relapsing multiple sclerosis clinical program

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

Variants in ZNF365 isoform D are associated with Crohn's disease

P512 Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib

Certolizumab pegol

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7‐year PREC i SE 3 study

Capsule Endoscopy: Practical Applications

Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM (R) MarketScan (R)

New Clinical Method for Distinguishing D-IBS from Other Gastrointestinal Conditions Causing Diarrhea: The LA/IBS Diagnostic Strategy

FRI0223 Development and Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) Gastrointestinal (GI) Symptom Scales in Systemic Sclerosis

Quality of life at the end of life: trends in patients with metastatic prostate cancer

Risk of Upper Gastrointestinal Injury and Events in Patients Treated With Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy: An Appraisal of the Literature

Suchergebnisse filtern